IMPORTANCE Women are at higher risk of drug-induced torsade de pointes (TdP) than men. Androgens are protective. Influence of oral contraception on drug-induced TdP and QT prolongation is controversial.
A prolonged heart rate-corrected QT interval (QTc) on electrocardiogram (ECG) is a marker of an increased risk of Torsades de Pointes (TdP).
1 Sex hormones modulate QTc and contribute to the longer QTc observed in the general population of women vs men and androgenized women. 1-3 Conversely, it has been proposed that QTc might be influenced by the androgenicity of oral contraceptive (OC) agents in women. 4 A major cause of drug-induced long QT syndrome (diLQTS) is inhibition of the rapid delayed rectifier potassium current, IKr. 5, 6 The present work is an addition to a prospective genetic study 7 in which healthy participants were challenged with a single low dose of sotalol (an IKr blocker); this study searched for genetic polymorphisms associated with excessive diLQTS. Oral contraceptive pills were the only treatment allowed before inclusion in that study. 7 The objective of this study is to assess the association between the extent of sotalol-induced QTc lengthening and appearance of ECG signs indicating IKr inhibition per the varying androgenic activity of OC pills taken by healthy women.
Methods

Study Design
From February 2008 to February 2012, 615 healthy women were enrolled in the Genome Wide Analysis of Sotalol-Induced IKr Inhibition During Ventricular Repolarization (GENEREPOL) study (NCT00773201). The study protocol received institutional review board approval from the Committee for the Protection of Human Subjects of Paris Ile de France V in Paris, France, and written informed consent was obtained from the participants. After enrollment, each participant received a single 80-mg oral dose of sotalol. 7 Because sotalol-induced LQTS represents the equivalent of an acquired form of congenital LQT2 syndrome (which involves a defect in IKr), 8 we evaluated ECG duration and morphology at baseline and the changes 3 hours after sotalol intake. 7 The inhibition of IKr is associated with QTc prolongation and the appearance of notches ( Figure 1 ). 7 We used the Fridericia correction 9,10 (QT/ 3 ͙RR, in which QT is the time from the start of the Q wave to the end of the T wave and RR is defined as the time from the onset of 1 QRS complex to the start of the next). Further details of the parent protocol are provided in the eAppendix in the Supplement. Long-term contraception was the only treatment allowed. The type of contraceptive modality was left at the discretion of the treating physician.
Nonmenopausal women were considered for this analysis if they were taking no oral contraception or if they had received any of the following OCs: levonorgestrel (a secondgeneration progestin with high androgenic potency), desogestrel or gestodene (a third-generation progestins with intermediate androgenic potency), or drospirenone (an antiandrogenic agent). 
Statistics
Disproportionality Analysis
The European database of suspected adverse drug reaction (ADR) reports 11 is a publicly accessible portal designed for searches of data on suspected ADR for authorized medicinal products in the European Economic Area. Disproportionality analyses (also known as case/noncase analyses) were performed for drospirenone vs levonorgestrel. 3, 12 This method compared the proportion of selected specific ADR reported for a single drug (drospirenone) with the proportion of the same ADR for a control drug (levonorgestrel). The denominators in these analyses were the overall ADRs reported for each drug. 3, 12 Reactions are based on the Medical Dictionary for Regulatory Activities classification. Disproportionality was estimated by calculating the reporting odds ratio (ROR). 3, 12, 13 We searched for ADRs arising from suspected OC-induced ventricular arrhythmias, cardiac deaths, and LQTS from inception until May 9, 2018.
12,13
Results
Of the 615 women initially recruited to this study, 498 were included (81.0%; Figure 2 (Table) . Baseline QTc duration was not significantly different among the groups taking OCs (Table) , and no notch was found in any participant. Three hours after sotalol administration (Table) , mean (SD) QTc prolongation differed among the groups taking OCs, ranging from 24.2 (13.7) milliseconds in the levonorgestrel group to 31.2 (12.6) milliseconds in the Changes in QTc duration were associated with plasma levels of sotalol 3 hours after drug exposure (r = 0.44; P < .001), kalemia (r =0.1;P = .05) but not with age or baseline QTc duration. Appearance of notching at 3 hours after exposure was associated with plasma levels of sotalol at 3 hours (r =0 .2; P < .001) but not with kalemia or age.
Multivariable analysis included plasma levels of sotalol at 3 hours, kalemia, and the type of OC used. The type of OC, plasma levels of sotalol at 3 hours after exposure (β = 0.44; SD, 0.04; P < .001) and kalemia (β = 0.08; SD, 0.04; P = .05) remained significant variables explaining change in QTc duration (r = 0.47; P < .001) in multivariable analysis. Compared with drospirenone, taking no OC and taking levonorgestrel were associated with less sotalol-induced QTc prolongation (taking no OC: β = -0.28; SD, 0.06; P < .001; and taking levonorgestrel: β = -0.19; SD, 0.06; P < .001).
Using multivariable logistic regression, the type of OC and plasma levels 3 hours after sotalol exposure (OR, 1.003 [95% CI, 1.002-1.005]; P < .001) remained significantly associated with notching at 3 hours after exposure. Sotalol-induced notches occurred more frequently in patients taking drospirenone than in the group taking no OC (OR, 2.32 [95% CI, 1.08-5.00]; P = .003).
The 
Discussion
To our knowledge, this is the first study comparing the association between type of OC used and the magnitude of QTc prolongation as a result of an IKr blocker in healthy volunteers. We showed that QTc prolongation and T-wave morphological changes are associated with the androgenic potency of the progestin taken, although absolute QTc prolongation was modest. Drospirenone, an OC with antiandrogenic properties, was associated with greater drug-induced QTc prolongation and appearance of T-wave notches, while levonorgestrel, a secondgeneration OC with high androgenic activity, was not. The upper limit of the IQR for the difference in QTc increase between drospirenone vs levonorgestrel was longer than 10 milliseconds, a threshold considered as associated with a potential increase of proarrhythmia risk. 9 However, this threshold is of unclear clinical significance, considering the nonrandomized nature of this relatively small study. Two to 5 times more women who were taking drosperinone developed a QTc prolongation of 50 milliseconds or longer compared with women taking either no OC or levonorgestrel. These results generate the hypothesis that drospirenone may be a risk factor for drug-induced TdP and sudden death in women receiving this OC. This hypothesis is also in line with the higher ROR for suspected OC-induced ventricular arrhythmias and cardiac death in women receiving drospirenone compared with levonorgestrel, as determined through analysis of the European pharmacovigilance database. More data are required on whether antiandrogenic OC use will lead to clinically significant adverse events in patients taking QTc-prolonging drugs, such as class III antiarrhythmic medications. Among the oral contraceptives included in the analysis, levonorgestrel was considered a second-generation progestin, desogestrel and gestodene third-generation progestins, and drospirenone a fourth-generation progestin.
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Sotalol is a potent IKr blocker with a dose-dependent risk of drug-induced TdP.
14 Sotalol was chosen because it has small pharmacokinetic variability, with a maximal concentration expected approximately 3 hours after oral intake. 15 We used a low single dose of sotalol (80 mg) for a standardized, shortacting, and safe IKr-blocking outcome. Therefore, the results of this study cannot provide a precise estimate of maximal drospirenone potential incremental association with sotalolinduced QTc prolongation and TdP risk in a real-life setting in which steady state is reached (160 to 320 mg per day, administered over the long term). Besides progesterone, which is the natural form of progestin, several parent compounds in the progestin family are used in OCs. These act on the progesterone receptor with variable bindings to other steroid hormone receptors. 16 Levonorgestrel has a high androgenic potency, while gestodene and desogestrel are less androgenic with better clinical acceptance. 16 Drospirenone has antiandrogenic properties. 16 
Limitations
Plasma endogenous or synthetic progestin levels (which vary between participants as a function of their weight, absorption, volume of distribution, and the timing of their last active OC intakes) were not assayed in this study. As a consequence, we were not able to take into consideration any potential higher sensitivity to diLQTS during the menstrual cycle in women taking no OCs or to evaluate the influence of progestin plasma levels at the time of ECG evaluations in women taking OCs. 17 Administration of OCs was not randomized in this study, but the main factors influencing QTc (kalemia and plasma sotalol levels) did not significantly differ among groups. Small but statistically significant differences of age existed between groups, but age was not associated with changes in QTc duration or notching at 3 hours in this cohort of women exclusively of child-bearing age. We acknowledge that pharmacovigilance epidemiological studies have mandatory limitations inherent to the lack of information on doses, associated drugs, and concomitant predisposing conditions, as well as imprecision in the exact number of individuals experiencing these events (vs ICSRs). They nevertheless remain a relevant method to detect signals in drug safety research and postmarketing surveillance, particularly for very rare ADRs, such as drug-induced TdP.
12, 13 The number of reports for a particular medicinal product may be influenced by the extent of use of the product, publicity, the nature of the reactions, and other factors, such as competition bias. Therefore, there is still a risk that comparisons of disproportionality between medicinal products in pharmacovigilance databases may be misleading. 18 
Conclusions
The findings of this study call for careful history-taking of OC use, and the type of OC taken could be useful in shared decision making in women with preexisting risk factors for druginduced TdP. 5 Abbreviations: IQR, interquartile range, NA, not applicable; QTc, corrected QT interval.
a P < .001 compared with drospirenone; P = .01-.05 compared with levonorgestrel, after post hoc test adjusted for multiple comparisons.
b P = .01 to .05 compared with no oral contraceptives, after post hoc test adjusted for multiple comparisons.
c P < .001 compared with no oral contraceptives.
d Evaluated by Cockcroft-Gault Equation; data were available for patients taking no oral contraceptives (n = 95), levonorgestrel (n = 48), desogestrel (n = 27), gestodene (n = 19), and drospirenone (n = 29).
e P = .01 to .001 compared with drospirenone after post hoc tests adjusted for multiple comparisons.
f P = .01 to .001 compared with no oral contraceptives, after post hoc test adjusted for multiple comparisons; P = .01 to .001 compared with levonorgestrel, after post hoc test adjusted for multiple comparisons.
g P = .01 to .001 compared with no oral contraceptives, after post hoc test adjusted for multiple comparisons; P = .01 to .001 compared with levonorgestrel, after post hoc test adjusted for multiple comparisons.
h P = .03 compared with drospirenone; P = .05 compared with gestodene.
i P = .05 compared with no oral contraceptives. j P = .03 compared with no oral contraceptives.
eAppendix. Methods. (References at the end of this document)
Study design
The GENEREPOL study 1 then, a continuous digital 12-lead ECG recording monitoring was started using a Cardioplug device (Cardionics Inc®, Brussels, Belgium) connected to a personal computer. Baseline ECG recordings (triplicate of 10-seconds each) were obtained after the subjects had rested for at least 10 minutes in the supine position. Each subject was then given a single oral dose of sotalol (80mg) and ECG monitoring was continuously pursued. Three hours post dosing (H3), 10-second ECG recordings were again extracted (triplicate) after the subjects had rested for at least 10 minutes in the supine position before lunch. At H3, a blood sample was drawn for the determination of plasma sotalol concentration. The participants were finally discharged 5 to 6
hours post dosing after verifying that their QTcF was < QTcF baseline + 40 msec.
Among all subjects included, 615 were women. Type, dose and timing of their chronic contraceptives modalities was left at the discretion of the treating physician and were unchanged for the purpose of this study. ) was chosen for QT correction on heart rate. 4, 5 QTc provided an accurate correction of QT for heart rate (r≤0.1 for QTc vs. heart rate regression). Analysis of ECGs was performed after inclusion of all subjects using CARDIABASE post-treatment software (Banook Group®, Nancy, France). 1 QTc was measured by the tangent method in Lead II on three consecutive beats and the mean value of a triplicate evaluation was retained. 6, 7 For QTc measurements, inter-and intra-observer agreements were periodically assessed using ICC (intra-class correlation coefficient) which was continuously measured >0.9, indicating an excellent agreement (hence interchangeability) and repeatability between operators.
For these quantitative parameters, the change (∆) between baseline and H3 value was calculated as follow:
∆ QTc (ms) = 3
∆ QTc (%) = 100
The assessment of notching was performed independently by two experienced observers (JES and CFB). A subject was considered as "notcher" when both observers agreed on the presence of a notch .
1
Concordance between observers was excellent ( =0.92±0.04).
All electrocardiographic analyses were performed blinded to any of the women's characteristics, including modalities of contraceptive treatment. 
